514 G3

Drug Profile

514 G3

Alternative Names: 514G3; True human™ monoclonal antibody - XBiotech

Latest Information Update: 20 Apr 2017

Price : $50

At a glance

  • Originator XBiotech
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Staphylococcal infections

Most Recent Events

  • 03 Apr 2017 Topline adverse events data from a phase I/II trial in Staphylococcal infections released by XBiotech
  • 01 Feb 2017 XBiotech completes a phase I/II trial in Staphylococcal infections in USA, Germany, Taiwan and South Korea (NCT02357966)
  • 06 Dec 2016 XBiotech completes enrolment in a phase I/II trial in Staphylococcal infections in USA, Germany, Taiwan and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top